ClinicalTrials.gg
RecruitingNCT07208786Updated Nov 2, 2026

Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery

An interventional study of PEVT in Colorectal Cancer, Colorectal Surgery and Complications, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
357th of 894
110 · median 80
Started
2025
with 124 others
No phase
150 of 1,139
81 open now
Primary completion
2026-10
later than 283 of 605 live
Registered
966th of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 357th largest by planned enrollment of the 894 interventional ones that give a count, is one of 125 that started in 2025, is one of 150 with no phase, reaches primary completion later than 283 of the 605 other live ones, and was the 966th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety and efficacy of postoperative Pre-emptive EVT (PEVT) in reducing the incidence of anastomotic leaks within 30 days after surgery in patients with colorectal cancer. Compare the differences between the PEVT group and the control group in terms of operation time, length of hospital stay, and total medical costs. Analyze the incidence of other postoperative complications in the two groups, such as wound infection, abdominal abscess, and intestinal obstruction. Assess the impact of PEVT on postoperative recovery indicators, including time to first flatus, time to first defecation, and time to ambulation. Observe the occurrence of PEVT-related adverse events, such as device displacement, bleeding, and infection.

03

Conditions studied

  • Colorectal Cancer
  • Colorectal Surgery
  • Complications
  • Anastomotic Leakage
  • Endoscopic Vacuum Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed with colorectal cancer, planned for radical surgery (right hemicolectomy, left hemicolectomy, or anterior resection of the rectum, etc.).
  2. Age 18-85 years, (ASA) classification I-III.
  3. Anastomosis to be performed in a single stage (meeting anastomotic criteria).
  4. Patient or legal guardian is able to understand and sign the form and comply with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Preexisting anastomotic leakage or severe intra-abdominal infection before surgery.
  2. Complicated by severe cardiovascular or cerebrovascular diseases (e.g., acute myocardial infarction, acute phase of cerebral infarction).
  3. Severe liver or kidney dysfunction (liver function class C, \<30 ml/min).
  4. Coagulation disorders ( \<50×10⁹/L, >1.5) or receiving anticoagulant therapy that cannot be adjusted.
  5. History of abdominal radiotherapy or multiple abdominal surgeries leading to severe intra-abdominal adhesions.
  6. Complicated by other malignant tumors and currently undergoing radiotherapy or chemotherapy.
  7. Psychiatric illness or cognitive impairment preventing compliance with the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Pre-emptive Endoscopic Vacuum Therapy

    After the anastomosis is completed and confirmed by endoscopy to be intact and free of bleeding, immediately perform Pre-emptive Endoscopic Vacuum Therapy(PEVT).

    Device: PEVT

  • No intervention
    No Pre-emptive Endoscopic Vacuum Therapy

    After the anastomosis, only routine colonoscopy was performed without PEVT device, and other steps were consistent with the PEVT group.

Interventions

  • DevicePEVT

    PEVT Procedures After the anastomosis is completed and endoscopy confirms that the anastomotic site is intact and without bleeding, the following procedures are carried out immediately (usually within 30 minutes after the completion of the anastomosis): 1. EVT device selection: Use an open-pore polyurethane sponge (OPPS) connected to a 16Fr nasogastric tube, with the sponge cut to a size of 2 cm × 3 cm. 2. Placement method: Insert the sponge through the anus to the anastomotic site in the intestinal lumen, set the negative pressure to low intensity (-50 to -100 mmHg), and connect to an external negative pressure suction device for continuous suction.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Anastomotic Leak within 30 days

    Count the number of participants who develop anastomotic leak within 30 days after colorectal cancer surgery.

    Time frame: 30 days

Secondary outcomes

  1. Number of Participants with Postoperative Complications within 30 days

    Count the number of participants who develop postoperative bleeding, anastomotic stenosis, and intra-abdominal infection within 30 days after colorectal cancer surgery.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Oct 2026, 12 months.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 12 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
Sep 22, 2025
Primary completionActual
Oct 10, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, date precision and design details
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07208786
Lead sponsor
Nanchong Central Hospital
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Sep 22, 2025
Primary completion
Oct 10, 2026
Completion
Dec 30, 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Yunhong Tian Tian, doctor
Contact
drtianyunhong@126.com
+8613508087719

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion